|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2004-5-11
|
|
pubmed:abstractText |
Recent studies have shown that type 2 diabetes is preventable by both lifestyle interventions and medications that influence primary glucose metabolism. Whether pharmacological interventions that influence primary lipid metabolism can also delay development of type 2 diabetes is unknown. The goal of this study was to evaluate the effect of the peroxisome proliferator-activated receptor ligand bezafibrate on the progression of impaired fasting glucose phase to type 2 diabetes in patients with coronary artery disease over a 6.2-year follow-up period.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
11
|
|
pubmed:volume |
109
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2197-202
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15123532-Aged,
pubmed-meshheading:15123532-Bezafibrate,
pubmed-meshheading:15123532-Blood Glucose,
pubmed-meshheading:15123532-Cholesterol,
pubmed-meshheading:15123532-Comorbidity,
pubmed-meshheading:15123532-Coronary Disease,
pubmed-meshheading:15123532-Diabetes Mellitus, Type 2,
pubmed-meshheading:15123532-Disease Progression,
pubmed-meshheading:15123532-Female,
pubmed-meshheading:15123532-Follow-Up Studies,
pubmed-meshheading:15123532-Glucose Intolerance,
pubmed-meshheading:15123532-Humans,
pubmed-meshheading:15123532-Hypercholesterolemia,
pubmed-meshheading:15123532-Hypolipidemic Agents,
pubmed-meshheading:15123532-Incidence,
pubmed-meshheading:15123532-Insulin,
pubmed-meshheading:15123532-Life Tables,
pubmed-meshheading:15123532-Male,
pubmed-meshheading:15123532-Middle Aged,
pubmed-meshheading:15123532-Myocardial Infarction,
pubmed-meshheading:15123532-Receptors, Cytoplasmic and Nuclear,
pubmed-meshheading:15123532-Transcription Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
|
|
pubmed:affiliation |
Cardiac Rehabilitation Institute, Chaim Sheba Medical Center, Tel-Hashomer, 52621 Israel. altenen@post.tau.ac.il
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|
